{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T07:03:06Z","timestamp":1793516586280,"version":"4.5.0"},"reference-count":345,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009399","name":"Peking University Third Hospital","doi-asserted-by":"publisher","award":["BYSYZD2021002"],"award-info":[{"award-number":["BYSYZD2021002"]}],"id":[{"id":"10.13039\/501100009399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173894"],"award-info":[{"award-number":["82173894"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003855"],"award-info":[{"award-number":["82003855"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.drup.2024.101195","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T19:07:42Z","timestamp":1735240062000},"page":"101195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Research progress on gene mutations and drug resistance in leukemia"],"prefix":"10.1016","volume":"79","author":[{"given":"Xiangyu","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1092-6272","authenticated-orcid":false,"given":"Joshua S.","family":"Fleishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Bing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boran","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6963-3293","authenticated-orcid":false,"given":"Letao","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1445-5994.2012.02938.x","article-title":"Leukaemias into the 21st century: part 1: the acute leukaemias","volume":"42","author":"Brown","year":"2012","journal-title":"Intern Med J."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2009.12.001","article-title":"Leukemia stem cells","volume":"20","author":"Lane","year":"2010","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.hoc.2019.08.020","article-title":"Hematologic malignancies","volume":"34","author":"Tseng","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.drup.2024.101195_bib5","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2017-12-778472","article-title":"Treatment strategies for adolescent and young adult patients with acute myeloid leukemia","volume":"132","author":"O'Dwyer","year":"2018","journal-title":"Blood"},{"issue":"10147","key":"10.1016\/j.drup.2024.101195_bib7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","article-title":"Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia","volume":"36","author":"de Beauchamp","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.drup.2024.101195_bib10","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute Lymphoblastic Leukemia in Children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib11","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ng.2558","article-title":"Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia","volume":"45","author":"Meyer","year":"2013","journal-title":"Nat. Genet"},{"key":"10.1016\/j.drup.2024.101195_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/asheducation-2008.1.391","article-title":"Curative strategies in acute promyelocytic leukemia","author":"Tallman","year":"2008","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0092-8674(91)90112-C","article-title":"Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML","volume":"66","author":"Kakizuka","year":"1991","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib15","doi-asserted-by":"crossref","first-page":"992","DOI":"10.18632\/oncotarget.27513","article-title":"Acute promyelocytic leukemia (APL): a review of the literature","volume":"11","author":"Jimenez","year":"2020","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.drup.2024.101195_bib16","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.canlet.2013.07.013","article-title":"Personalized medicine in CLL: current status and future perspectives","volume":"352","author":"Rozovski","year":"2014","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.drup.2024.101195_bib18","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Goldman","year":"2001","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2024.101195_bib19","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.2147\/JIR.S350109","article-title":"Microglia-mediated neuroinflammation: a potential target for the treatment of cardiovascular diseases","volume":"15","author":"Wang","year":"2022","journal-title":"J. Inflamm. Res"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib20","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/sj.leu.2402912","article-title":"Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies","volume":"17","author":"Clarkson","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000468","article-title":"Chronic Myeloid Leukemia in 2020","volume":"4","author":"Hehlmann","year":"2020","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3324\/haematol.2019.225003","article-title":"Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia","volume":"105","author":"Bill","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib23","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","article-title":"BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia","volume":"285","author":"Yuan","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"9881","key":"10.1016\/j.drup.2024.101195_bib24","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.drup.2024.101195_bib25","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.drup.2024.101195_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1756-8722-3-41","article-title":"The frequency of NPM1 mutations in childhood acute myeloid leukemia","volume":"3","author":"Braoudaki","year":"2010","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V26.5.642.642","article-title":"The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia","volume":"26","author":"Frei","year":"1965","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.drup.2024.101195_bib28","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","article-title":"Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group","volume":"30","author":"Bhatia","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"7689","key":"10.1016\/j.drup.2024.101195_bib29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nature25186","article-title":"Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia","volume":"553","author":"Tzoneva","year":"2018","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.drup.2024.101195_bib30","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1182\/blood-2011-04-345595","article-title":"Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies","volume":"118","author":"Hogan","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.drup.2024.101195_bib31","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood-2019-01-852392","article-title":"Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL","volume":"133","author":"Dieck","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib32","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1158\/1535-7163.MCT-18-1112","article-title":"Mechanisms of NT5C2-mediated thiopurine resistance in acute lymphoblastic Leukemia","volume":"18","author":"Moriyama","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.3078","article-title":"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL","volume":"19","author":"Tzoneva","year":"2013","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2024.101195_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejmech.2014.02.055","article-title":"Structure-activity relationships of beta-hydroxyphosphonate nucleoside analogues as cytosolic 5\u2032-nucleotidase II potential inhibitors: synthesis, in vitro evaluation and molecular modeling studies","volume":"77","author":"Meurillon","year":"2014","journal-title":"Eur. J. Med Chem."},{"issue":"24","key":"10.1016\/j.drup.2024.101195_bib35","doi-asserted-by":"crossref","first-page":"9680","DOI":"10.1021\/acs.jmedchem.5b01616","article-title":"Identification of noncompetitive inhibitors of cytosolic 5\u2032-nucleotidase ii using a fragment-based approach","volume":"58","author":"Marton","year":"2015","journal-title":"J. Med Chem."},{"issue":"6170","key":"10.1016\/j.drup.2024.101195_bib36","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1126\/science.1247363","article-title":"Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders","volume":"343","author":"Novarino","year":"2014","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.drup.2024.101195_bib37","first-page":"3537","article-title":"Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines","volume":"57","author":"Kool","year":"1997","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1152\/physrev.00035.2005","article-title":"Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins","volume":"86","author":"Deeley","year":"2006","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00424-006-0054-9","article-title":"Multidrug resistance-associated proteins 3, 4, and 5","volume":"453","author":"Borst","year":"2007","journal-title":"Pflug. Arch."},{"issue":"47","key":"10.1016\/j.drup.2024.101195_bib40","doi-asserted-by":"crossref","first-page":"48855","DOI":"10.1074\/jbc.M408849200","article-title":"Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state","volume":"279","author":"Sauna","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"Pt 2","key":"10.1016\/j.drup.2024.101195_bib41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/bj20021886","article-title":"Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4)","volume":"371","author":"Zelcer","year":"2003","journal-title":"Biochem J."},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib42","first-page":"3144","article-title":"Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system","volume":"62","author":"Chen","year":"2002","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tips.2008.01.006","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4): a versatile efflux transporter for drugs and signalling molecules","volume":"29","author":"Russel","year":"2008","journal-title":"Trends Pharm. Sci."},{"issue":"39","key":"10.1016\/j.drup.2024.101195_bib44","doi-asserted-by":"crossref","first-page":"30069","DOI":"10.1074\/jbc.M005463200","article-title":"The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides","volume":"275","author":"Jedlitschky","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib45","first-page":"988","article-title":"Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump","volume":"56","author":"Jedlitschky","year":"1996","journal-title":"Cancer Res"},{"issue":"36","key":"10.1016\/j.drup.2024.101195_bib46","doi-asserted-by":"crossref","first-page":"33747","DOI":"10.1074\/jbc.M104833200","article-title":"Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine","volume":"276","author":"Chen","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0888-7543(90)90043-T","article-title":"Cloning of cDNAs for human phosphoribosylpyrophosphate synthetases 1 and 2 and X chromosome localization of PRPS1 and PRPS2 genes","volume":"8","author":"Becker","year":"1990","journal-title":"Genomics"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib48","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0167-4781(97)00217-0","article-title":"Molecular cloning of a human cDNA for the 41-kDa phosphoribosylpyrophosphate synthetase-associated protein","volume":"1396","author":"Katashima","year":"1998","journal-title":"Biochim Biophys. Acta"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12031-016-0783-y","article-title":"Phosphoribosylpyrophosphate Synthetase 1 Knockdown Suppresses Tumor Formation of Glioma CD133+\u2009cells through upregulating cell apoptosis","volume":"60","author":"Li","year":"2016","journal-title":"J. Mol. Neurosci."},{"issue":"14","key":"10.1016\/j.drup.2024.101195_bib50","doi-asserted-by":"crossref","first-page":"10168","DOI":"10.1016\/S0021-9258(18)82187-1","article-title":"Overexpression, purification, and characterization of recombinant human 5-phosphoribosyl-1-pyrophosphate synthetase isozymes I and II","volume":"268","author":"Nosal","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nm.3840","article-title":"Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL","volume":"21","author":"Li","year":"2015","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib52","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1172\/JCI118267","article-title":"The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity","volume":"96","author":"Becker","year":"1995","journal-title":"J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib53","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ajhg.2010.02.024","article-title":"PRPS1 mutations: four distinct syndromes and potential treatment","volume":"86","author":"de Brouwer","year":"2010","journal-title":"Am. J. Hum. Genet"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib54","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajmg.a.34428","article-title":"Phosphoribosylpyrophosphate synthetase superactivity and recurrent infections is caused by a p.Val142Leu mutation in PRS-I","volume":"158A","author":"Moran","year":"2012","journal-title":"Am. J. Med Genet A"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib55","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1111\/jcmm.13907","article-title":"Increase of PRPP enhances chemosensitivity of PRPS1 mutant acute lymphoblastic leukemia cells to 5-Fluorouracil","volume":"22","author":"Wang","year":"2018","journal-title":"J. Cell Mol. Med"},{"issue":"23","key":"10.1016\/j.drup.2024.101195_bib56","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.drup.2024.101195_bib57","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","volume":"14","author":"Hamed","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib58","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","article-title":"Polyglutamation of methotrexate. Is methotrexate a prodrug?","volume":"76","author":"Chabner","year":"1985","journal-title":"J. Clin. Invest"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib59","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41375-021-01189-2","article-title":"Folate metabolism: a re-emerging therapeutic target in haematological cancers","volume":"35","author":"Zarou","year":"2021","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.drup.2024.101195_bib60","first-page":"6030","article-title":"Structural organization of the human folypoly-gamma-glutamate synthetase gene: evidence for a single genomic locus","volume":"55","author":"Taylor","year":"1995","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib61","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.7314\/APJCP.2015.16.11.4727","article-title":"Mutation screening and association study of the folylpolyglutamate synthetase (FPGS) gene with susceptibility to childhood acute lymphoblastic leukemia","volume":"16","author":"Piwkham","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"18","key":"10.1016\/j.drup.2024.101195_bib62","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1158\/0008-5472.CAN-07-0156","article-title":"Identification and characterization of genetic variation in the folylpolyglutamate synthase gene","volume":"67","author":"Leil","year":"2007","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.2019002220","article-title":"Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia","volume":"135","author":"Li","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib64","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1006\/jmbi.2001.4815","article-title":"Folate-binding triggers the activation of folylpolyglutamate synthetase","volume":"310","author":"Sun","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/sj.leu.2402373","article-title":"Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine","volume":"16","author":"Dervieux","year":"2002","journal-title":"Leukemia"},{"issue":"7337","key":"10.1016\/j.drup.2024.101195_bib66","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.drup.2024.101195_bib67","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1101\/gad.14.13.1553","article-title":"CBP\/p300 in cell growth, transformation, and development","volume":"14","author":"Goodman","year":"2000","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib68","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/nar\/gkh252","article-title":"The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases","volume":"32","author":"Yang","year":"2004","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib69","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1101\/gad.14.3.272","article-title":"Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP","volume":"14","author":"Kung","year":"2000","journal-title":"Genes Dev."},{"issue":"7-8","key":"10.1016\/j.drup.2024.101195_bib70","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.biocel.2007.03.009","article-title":"HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway","volume":"39","author":"Tsapis","year":"2007","journal-title":"Int J. Biochem Cell Biol."},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib71","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib72","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"6630","key":"10.1016\/j.drup.2024.101195_bib73","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-5793(97)01480-4","article-title":"Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53","volume":"420","author":"Honda","year":"1997","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib75","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","article-title":"Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a","volume":"88","author":"Serrano","year":"1997","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib76","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molcel.2005.03.027","article-title":"AMP-activated protein kinase induces a p53-dependent metabolic checkpoint","volume":"18","author":"Jones","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drup.2024.101195_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/srep28112","article-title":"Histone modifications and p53 binding poise the p21 promoter for activation in human embryonic stem cells","volume":"6","author":"Itahana","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib78","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib79","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.beha.2018.09.010","article-title":"Patterns of mutations in TP53 mutated AML","volume":"31","author":"Welch","year":"2018","journal-title":"Best. Pr. Res Clin. Haematol."},{"key":"10.1016\/j.drup.2024.101195_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.59","article-title":"TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution","volume":"5","author":"Hou","year":"2015","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib81","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2024.101195_bib82","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fonc.2015.00276","article-title":"The Contrived mutant p53 oncogene - beyond loss of functions","volume":"5","author":"Sabapathy","year":"2015","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib83","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.cdd.4401194","article-title":"Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy","volume":"10","author":"Sturm","year":"2003","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib84","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cpt.2023.10.002","article-title":"Next-generation sequencing reveals relapse and leukemia-free survival risks in newly diagnosed acute myeloid leukemia treated with CAG regimen combined with decitabine","volume":"2","author":"Huang","year":"2024","journal-title":"Cancer Pathog. Ther."},{"issue":"3 2","key":"10.1016\/j.drup.2024.101195_bib85","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1053\/j.seminhematol.2008.07.007","article-title":"Targeting FLT3 for the treatment of leukemia","volume":"45","author":"Small","year":"2008","journal-title":"Semin Hematol."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib86","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089","article-title":"Expression of the hematopoietic growth factor receptor FLT3 (STK-1\/Flk2) in human leukemias","volume":"87","author":"Carow","year":"1996","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib87","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib88","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00062752-200207000-00003","article-title":"Role of FLT3 in leukemia","volume":"9","author":"Gilliland","year":"2002","journal-title":"Curr. Opin. Hematol."},{"issue":"7397","key":"10.1016\/j.drup.2024.101195_bib89","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib90","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.3324\/haematol.2016.162206","article-title":"Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse","volume":"102","author":"Fasan","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib91","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/leu.2016.237","article-title":"Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia","volume":"30","author":"Madan","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib92","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.25573","article-title":"Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse","volume":"94","author":"Iaccarino","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.drup.2024.101195_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091311","article-title":"The Impact of Flt3 gene mutations in acute promyelocytic leukemia: a meta-analysis","volume":"11","author":"Picharski","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1016\/j.drup.2024.101195_bib94","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood.2021011582","article-title":"Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression","volume":"138","author":"Lv","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib95","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2007-05-092510","article-title":"Internal tandem duplication of FLT3 (FLT3\/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML","volume":"111","author":"Sallmyr","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib96","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2402740","article-title":"FLT3 mutations in acute myeloid leukemia cell lines","volume":"17","author":"Quentmeier","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib97","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.drup.2024.101195_bib98","first-page":"5465","article-title":"An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients","volume":"9","author":"O'Farrell","year":"2003","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib99","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12867-016-0073-9","article-title":"Nucleophosmin: from structure and function to disease development","volume":"17","author":"Box","year":"2016","journal-title":"BMC Mol. Biol."},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib101","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib102","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2005-04-1733","article-title":"Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia","volume":"106","author":"Suzuki","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib103","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000496097","article-title":"Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia","volume":"141","author":"Bain","year":"2019","journal-title":"Acta Haematol."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib104","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood.V87.3.882.bloodjournal873882","article-title":"The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion","volume":"87","author":"Redner","year":"1996","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.drup.2024.101195_bib105","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1182\/blood.2021012732","article-title":"Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML","volume":"138","author":"Martelli","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib106","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med"},{"issue":"25","key":"10.1016\/j.drup.2024.101195_bib107","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood.2019001240","article-title":"Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT","volume":"134","author":"Borrow","year":"2019","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.drup.2024.101195_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810040","article-title":"Significance of NPM1 gene mutations in AML","volume":"22","author":"Hindley","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.drup.2024.101195_bib109","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","article-title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","volume":"129","author":"Garzon","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib110","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"Kuhn","year":"2016","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib111","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJMc1509584","article-title":"Dactinomycin in NPM1-mutated acute myeloid leukemia","volume":"373","author":"Falini","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib112","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41551-020-00625-5","article-title":"CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia","volume":"5","author":"Xie","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib113","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1574892817666220429105338","article-title":"Venetoclax in acute myeloid leukemia","volume":"18","author":"Mihaila","year":"2023","journal-title":"Recent Pat. Anticancer Drug Discov."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib114","first-page":"845","article-title":"Identification and characterization of ASXL2 gene in silico","volume":"23","author":"Katoh","year":"2003","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.drup.2024.101195_bib115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0378-1119(03)00430-X","article-title":"A human homolog of Additional sex combs, additional sex COMBS-LIKE 1, maps to chromosome 20q11","volume":"306","author":"Fisher","year":"2003","journal-title":"Gene"},{"issue":"13","key":"10.1016\/j.drup.2024.101195_bib116","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00018-019-03084-7","article-title":"The role of ASXL1 in hematopoiesis and myeloid malignancies","volume":"76","author":"Asada","year":"2019","journal-title":"Cell Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib117","first-page":"60","article-title":"ASXL1 Gene in AML","volume":"47","author":"Hurtado","year":"2021","journal-title":"J. Assoc. Genet Technol."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib118","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/leu.2009.218","article-title":"Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias","volume":"24","author":"Carbuccia","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib119","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2014.114157","article-title":"ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian acute myeloid leukemia study group","volume":"100","author":"Paschka","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib120","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ajmg.a.31265","article-title":"New cases of Bohring-Opitz syndrome, update, and critical review of the literature","volume":"140","author":"Bohring","year":"2006","journal-title":"Am. J. Med Genet A"},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib121","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1172\/JCI70739","article-title":"Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations","volume":"123","author":"Inoue","year":"2013","journal-title":"J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib122","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.exphem.2015.11.011","article-title":"Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels","volume":"44","author":"Inoue","year":"2016","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib123","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet"},{"key":"10.1016\/j.drup.2024.101195_bib124","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-5-12","article-title":"Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases","volume":"5","author":"Gelsi-Boyer","year":"2012","journal-title":"J. Hematol. Oncol."},{"issue":"7295","key":"10.1016\/j.drup.2024.101195_bib125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drup.2024.101195_bib126","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.exphem.2020.01.002","article-title":"ASXL1 mutation in clonal hematopoiesis","volume":"83","author":"Fujino","year":"2020","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib127","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12185-018-2563-7","article-title":"Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms","volume":"110","author":"Asada","year":"2019","journal-title":"Int J. Hematol."},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-022-01336-x","article-title":"ASXL1\/2 mutations and myeloid malignancies","volume":"15","author":"Medina","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib129","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1182\/blood.2021012519","article-title":"Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation","volume":"139","author":"You","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.drup.2024.101195_bib130","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood.2019003357","article-title":"High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML","volume":"135","author":"Simon","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.drup.2024.101195_bib131","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2016-10-687830","article-title":"Role of RUNX1 in hematological malignancies","volume":"129","author":"Sood","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib132","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ejhg.2008.89","article-title":"Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions","volume":"16","author":"Beri-Dexheimer","year":"2008","journal-title":"Eur. J. Hum. Genet"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib133","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/09537104.2017.1280151","article-title":"Gene of the issue: RUNX1 mutations and inherited bleeding","volume":"28","author":"Morgan","year":"2017","journal-title":"Platelets"},{"issue":"15","key":"10.1016\/j.drup.2024.101195_bib134","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1182\/blood-2016-12-689109","article-title":"Runx transcription factors in the development and function of the definitive hematopoietic system","volume":"129","author":"de Bruijn","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib135","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/ijc.27964","article-title":"RUNX family: regulation and diversification of roles through interacting proteins","volume":"132","author":"Chuang","year":"2013","journal-title":"Int J. Cancer"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gcc.10246","article-title":"AML1\/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies","volume":"38","author":"Taketani","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib137","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2009-11-255976","article-title":"RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis","volume":"117","author":"Schnittger","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib138","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3324\/haematol.2012.064667","article-title":"RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes","volume":"97","author":"Greif","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib139","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14728222.2021.1915991","article-title":"Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications","volume":"25","author":"Gonzales","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib140","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/890","article-title":"Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases","volume":"19","author":"Okano","year":"1998","journal-title":"Nat. Genet"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib141","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2013.65","article-title":"Landmark analysis of DNMT3A mutations in hematological malignancies","volume":"27","author":"Roller","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib142","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1242\/dev.129.8.1983","article-title":"Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice","volume":"129","author":"Hata","year":"2002","journal-title":"Development"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib143","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0378-1119(99)00252-8","article-title":"Cloning, expression and chromosome locations of the human DNMT3 gene family","volume":"236","author":"Xie","year":"1999","journal-title":"Gene"},{"issue":"41","key":"10.1016\/j.drup.2024.101195_bib144","doi-asserted-by":"crossref","first-page":"38746","DOI":"10.1074\/jbc.M205312200","article-title":"A novel Dnmt3a isoform produced from an alternative promoter localizes to euchromatin and its expression correlates with active de novo methylation","volume":"277","author":"Chen","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib145","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030320","article-title":"DNMT3A in Leukemia","volume":"7","author":"Brunetti","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med"},{"issue":"23","key":"10.1016\/j.drup.2024.101195_bib146","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1182\/blood-2012-10-461624","article-title":"Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)","volume":"121","author":"Gaidzik","year":"2013","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.drup.2024.101195_bib147","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1200\/JCO.2014.59.2022","article-title":"Simpson's paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia","volume":"33","author":"Gale","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"37","key":"10.1016\/j.drup.2024.101195_bib148","doi-asserted-by":"crossref","first-page":"30941","DOI":"10.1074\/jbc.M112.366625","article-title":"Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation","volume":"287","author":"Holz-Schietinger","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"25","key":"10.1016\/j.drup.2024.101195_bib149","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2013-02-483487","article-title":"A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells","volume":"122","author":"Kim","year":"2013","journal-title":"Blood"},{"issue":"48","key":"10.1016\/j.drup.2024.101195_bib150","doi-asserted-by":"crossref","first-page":"41479","DOI":"10.1074\/jbc.M111.284687","article-title":"Oligomerization of DNMT3A controls the mechanism of de novo DNA methylation","volume":"286","author":"Holz-Schietinger","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib151","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","article-title":"The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers","volume":"25","author":"Russler-Germain","year":"2014","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.drup.2024.101195_bib152","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib153","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4161\/epi.29315","article-title":"Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes","volume":"9","author":"Qu","year":"2014","journal-title":"Epigenetics"},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib154","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1158\/2159-8290.CD-16-0008","article-title":"DNMT3A Haploinsufficiency transforms FLT3ITD myeloproliferative disease into a rapid, spontaneous, and fully penetrant acute myeloid leukemia","volume":"6","author":"Meyer","year":"2016","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib155","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2016.05.003","article-title":"DNMT3A loss drives enhancer hypomethylation in FLT3-ITD-associated leukemias","volume":"29","author":"Yang","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2024.101195_bib156","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10924","article-title":"DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation","volume":"7","author":"Koya","year":"2016","journal-title":"Nat. Commun."},{"issue":"25","key":"10.1016\/j.drup.2024.101195_bib157","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"21","key":"10.1016\/j.drup.2024.101195_bib158","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","article-title":"Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia","volume":"29","author":"Thol","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib159","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3324\/haematol.2011.051581","article-title":"Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia","volume":"97","author":"Fried","year":"2012","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.drup.2024.101195_bib160","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.608.608","article-title":"Whole-genome bisulfite sequencing of primary AML Cells with the DNMT3A R882H mutation identifies regions of focal hypomethylation that are associated with open chromatin","volume":"124","author":"Spencer","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib161","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nbt.2800","article-title":"Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library","volume":"32","author":"Koike-Yusa","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib162","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.molcel.2013.12.001","article-title":"Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia","volume":"53","author":"Cao","year":"2014","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib163","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","article-title":"Acquired mutations in TET2 are common in myelodysplastic syndromes","volume":"41","author":"Langemeijer","year":"2009","journal-title":"Nat. Genet"},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib164","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMc091348","article-title":"Mutation in TET2 in myeloid cancers","volume":"361","author":"Tefferi","year":"2009","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib165","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib166","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2009-01-197525","article-title":"Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms","volume":"114","author":"Saint-Martin","year":"2009","journal-title":"Blood"},{"issue":"5929","key":"10.1016\/j.drup.2024.101195_bib167","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.drup.2024.101195_bib168","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.V114.22.2908.2908","article-title":"Involvement of TET2 in regulation of epigenetic silencing in MDS and related myeloid malignancies","volume":"114","author":"Szpurka","year":"2009","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.drup.2024.101195_bib169","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2110758118","article-title":"TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia","volume":"118","author":"Bensberg","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib170","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 function blocks aberrant self-renewal and leukemia progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib171","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ccell.2017.10.002","article-title":"Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure","volume":"32","author":"de The","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib172","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.01.005","article-title":"A sumoylation site in PML\/RARA is essential for leukemic transformation","volume":"7","author":"Zhu","year":"2005","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib173","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/cdd.2016.111","article-title":"The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway","volume":"24","author":"Chen","year":"2017","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib174","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"5975","key":"10.1016\/j.drup.2024.101195_bib175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1126\/science.1183424","article-title":"Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML","volume":"328","author":"Zhang","year":"2010","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.drup.2024.101195_bib176","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1073\/pnas.0400053101","article-title":"All-trans retinoic acid\/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia","volume":"101","author":"Shen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"16","key":"10.1016\/j.drup.2024.101195_bib177","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2009-01-198911","article-title":"Differentiation therapy of leukemia: 3 decades of development","volume":"113","author":"Nowak","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib178","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41418-023-01139-8","article-title":"Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARalpha","volume":"30","author":"Dai","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.drup.2024.101195_bib179","article-title":"The histone deacetylase inhibitor I13 Induces Differentiation of M2, M3 and M5 subtypes of acute myeloid leukemia cells and leukemic stem-like cells","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib180","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41375-018-0139-4","article-title":"Management of patients with acute promyelocytic leukemia","volume":"32","author":"Kayser","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib181","first-page":"1281","article-title":"A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features","volume":"6","author":"Duprez","year":"1992","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib182","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.leu.2401683","article-title":"A mutated PML\/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML\/RARA transcriptional activities","volume":"14","author":"Duprez","year":"2000","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.drup.2024.101195_bib183","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/blood.V96.9.3200","article-title":"Altered ligand binding and transcriptional regulation by mutations in the PML\/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia","volume":"96","author":"Cote","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib184","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s12185-013-1354-4","article-title":"Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia","volume":"97","author":"Tomita","year":"2013","journal-title":"Int J. Hematol."},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib185","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2012-01-407601","article-title":"Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia","volume":"120","author":"Gallagher","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib186","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2011-01-329433","article-title":"Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment","volume":"118","author":"Goto","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib187","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2011-10-388496","article-title":"The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML\/RARA through inhibition of PML body recycling","volume":"120","author":"Lang","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib188","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/blood-2011-06-357566","article-title":"Mutants strike again in APL","volume":"118","author":"Gallagher","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib189","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1158\/2159-8290.CD-23-0453","article-title":"Structural Basis of PML-RARA oncoprotein targeting by arsenic unravels a cysteine rheostat controlling PML body assembly and function","volume":"13","author":"Bercier","year":"2023","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051504","article-title":"Next generation BTK inhibitors in CLL: evolving challenges and new opportunities","volume":"15","author":"Frustaci","year":"2023","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.drup.2024.101195_bib191","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2024.101195_bib192","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-065X.2000.imr017504.x","article-title":"Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective","volume":"175","author":"Satterthwaite","year":"2000","journal-title":"Immunol. Rev."},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib193","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drup.2024.101195_bib194","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2147\/JEP.S265284","article-title":"The Role of BTK inhibition in the treatment of chronic lymphocytic leukemia: a clinical view","volume":"13","author":"Tambaro","year":"2021","journal-title":"J. Exp. Pharm."},{"issue":"9","key":"10.1016\/j.drup.2024.101195_bib195","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib196","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/17474086.2020.1797482","article-title":"Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies","volume":"13","author":"Lama","year":"2020","journal-title":"Expert Rev. Hematol."},{"issue":"24","key":"10.1016\/j.drup.2024.101195_bib197","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib198","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121834","article-title":"Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia","volume":"11","author":"Pula","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib199","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/leu.2017.110","article-title":"PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment","volume":"31","author":"Jones","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib200","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib201","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2024.101195_bib202","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-016-0837-5","article-title":"Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia","volume":"14","author":"Zheng","year":"2016","journal-title":"J. Transl. Med"},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib203","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.clml.2022.07.013","article-title":"SOHO state of the art updates and next questions | mechanisms of resistance to BCL2 inhibitor therapy in chronic lymphocytic leukemia and potential future therapeutic directions","volume":"22","author":"Bennett","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib204","first-page":"456","article-title":"Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2024.101195_bib205","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/943648","article-title":"Targeting BCL2-proteins for the treatment of solid tumours","volume":"2014","author":"Vogler","year":"2014","journal-title":"Adv. Med."},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib206","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib207","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2024.101195_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: an update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist Updat"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib209","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val Mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.drup.2024.101195_bib210","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib211","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib212","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.drup.2024.101195_bib213","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib214","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J. Pers. Med"},{"issue":"34","key":"10.1016\/j.drup.2024.101195_bib215","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE Study","volume":"39","author":"Wierda","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.drup.2024.101195_bib216","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib217","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010117","article-title":"Chronic myeloid leukemia: a model disease of the past, present and future","volume":"10","author":"Minciacchi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.drup.2024.101195_bib218","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fonc.2018.00229","article-title":"NOTCH1 aberrations in chronic lymphocytic leukemia","volume":"8","author":"Rosati","year":"2018","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib219","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/leu.2017.296","article-title":"NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-kappaB pathways","volume":"32","author":"Benedetti","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib220","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1084\/jem.20111855","article-title":"Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think","volume":"208","author":"Lobry","year":"2011","journal-title":"J. Exp. Med"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib221","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2141.2009.07816.x","article-title":"A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation","volume":"146","author":"Di Ianni","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib222","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J. Exp. Med"},{"issue":"7354","key":"10.1016\/j.drup.2024.101195_bib223","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib224","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood-2008-02-139725","article-title":"Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells","volume":"113","author":"Rosati","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib225","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2141.2010.08368.x","article-title":"NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL","volume":"151","author":"Sportoletti","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.drup.2024.101195_bib226","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib227","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"9980","key":"10.1016\/j.drup.2024.101195_bib228","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib229","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210374","article-title":"Treatment refractoriness in chronic lymphocytic leukemia: old and new molecular biomarkers","volume":"24","author":"Maher","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib230","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/leu.2015.182","article-title":"NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation","volume":"30","author":"Pozzo","year":"2016","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.drup.2024.101195_bib231","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3227.3227","article-title":"Gene mutations and treatment outcome in the context of chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - results of an extensive analysis of the phase III Study CLL11 of the German CLL study group","volume":"128","author":"Estenfelder","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.drup.2024.101195_bib232","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib233","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib234","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.drup.2024.101195_bib235","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib236","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3324\/haematol.2019.219550","article-title":"Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia","volume":"105","author":"Diop","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib237","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1158\/1078-0432.CCR-18-1548","article-title":"BIRC3 expression predicts CLL progression and defines treatment sensitivity via enhanced NF-kappaB nuclear translocation","volume":"25","author":"Asslaber","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"7574","key":"10.1016\/j.drup.2024.101195_bib238","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib239","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.drup.2024.101195_bib240","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"issue":"9747","key":"10.1016\/j.drup.2024.101195_bib241","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib242","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cell.2007.10.037","article-title":"IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis","volume":"131","author":"Vince","year":"2007","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib243","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","article-title":"Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications","volume":"109","author":"Jost","year":"2007","journal-title":"Blood"},{"issue":"5405","key":"10.1016\/j.drup.2024.101195_bib244","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib245","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13238-010-0016-z","article-title":"Molecular and cellular bases of chronic myeloid leukemia","volume":"1","author":"Chen","year":"2010","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib246","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14656566.2014.850491","article-title":"Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?","volume":"15","author":"Visani","year":"2014","journal-title":"Expert Opin. Pharm."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib247","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review","volume":"93","author":"Yang","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib248","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib249","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11899-012-0114-5","article-title":"Genetic mechanisms of chronic myeloid leukemia blastic transformation","volume":"7","author":"Skorski","year":"2012","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib250","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib251","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib252","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib253","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.canlet.2011.08.009","article-title":"Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients","volume":"312","author":"Tanaka","year":"2011","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib254","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/leu.2009.79","article-title":"LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome","volume":"23","author":"Soler","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2024.101195_bib255","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cancergen.2023.08.004","article-title":"Acute myeloid leukemia with LRRFIP1::FGFR1 rearrangement and a complex karyotype","volume":"278-279","author":"Qian","year":"2023","journal-title":"Cancer Genet"},{"key":"10.1016\/j.drup.2024.101195_bib256","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cancergen.2023.02.002","article-title":"Unexpected appearance of KMT2A::MLLT10 fusion transcript in acute myeloid leukemia with t(5;11)(q31;q23.3)","volume":"272-273","author":"Yamamoto","year":"2023","journal-title":"Cancer Genet"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib257","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/bloodadvances.2023010805","article-title":"Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia","volume":"8","author":"Abla","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.drup.2024.101195_bib258","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cancergen.2024.03.004","article-title":"Rare NUP98::PRRX1 fusion transcript in a therapy-related acute myeloid leukemia associated with del(7q) following chemotherapy for diffuse large B-cell lymphoma","volume":"284-285","author":"Wang","year":"2024","journal-title":"Cancer Genet"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib259","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"14","key":"10.1016\/j.drup.2024.101195_bib260","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21144885","article-title":"Nucleophosmin in Its Interaction with Ligands","volume":"21","author":"Cela","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib261","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrc1885","article-title":"Nucleophosmin and cancer","volume":"6","author":"Grisendi","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"30","key":"10.1016\/j.drup.2024.101195_bib262","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/onc.2008.54","article-title":"NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells","volume":"27","author":"Qi","year":"2008","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib263","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1182\/blood-2010-09-309674","article-title":"Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1","volume":"118","author":"Balusu","year":"2011","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.drup.2024.101195_bib264","doi-asserted-by":"crossref","first-page":"23326","DOI":"10.1074\/jbc.M801706200","article-title":"Structural consequences of nucleophosmin mutations in acute myeloid leukemia","volume":"283","author":"Grummitt","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.drup.2024.101195_bib265","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/pro.2240","article-title":"Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization","volume":"22","author":"Federici","year":"2013","journal-title":"Protein Sci."},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib266","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/leu.2009.124","article-title":"Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications","volume":"23","author":"Falini","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib267","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.392","article-title":"Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia","volume":"7","author":"Andresen","year":"2016","journal-title":"Cell Death Dis."},{"issue":"9","key":"10.1016\/j.drup.2024.101195_bib268","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/cncr.30515","article-title":"Imidazoquinoxaline derivative EAPB0503: a promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia","volume":"123","author":"Nabbouh","year":"2017","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib269","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073421","article-title":"EAPB0503, an imidazoquinoxaline derivative modulates SENP3\/ARF Mediated SUMOylation, and Induces NPM1c degradation in NPM1 mutant AML","volume":"23","author":"Skayneh","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib270","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib271","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib272","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccell.2019.01.013","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"35","author":"Jones","year":"2019","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib273","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib274","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","article-title":"Genetic characterization of ABT-199 sensitivity in human AML","volume":"34","author":"Bisaillon","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib276","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2005-02-0560","article-title":"Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance","volume":"106","author":"Alcalay","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib277","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2016.222","article-title":"HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia","volume":"31","author":"Kontro","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib278","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/2159-8290.CD-21-0177","article-title":"Actinomycin D targets NPM1c-primed mitochondria to restore PML-driven senescence in AML therapy","volume":"11","author":"Wu","year":"2021","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib279","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/bloodadvances.2019000359","article-title":"Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies","volume":"4","author":"Fischer","year":"2020","journal-title":"Blood Adv."},{"issue":"17","key":"10.1016\/j.drup.2024.101195_bib280","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood.2021011917","article-title":"Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1\/FLT3-mutated AML","volume":"138","author":"Carter","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib281","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib282","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1002\/ajh.25719","article-title":"Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation","volume":"95","author":"Zhu","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib283","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","article-title":"Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML","volume":"118","author":"Helgason","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib284","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s13238-021-00841-y","article-title":"Ferroptosis, radiotherapy, and combination therapeutic strategies","volume":"12","author":"Lei","year":"2021","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib285","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4143\/crt.2016.572","article-title":"Ferroptosis: a novel anti-tumor action for cisplatin","volume":"50","author":"Guo","year":"2018","journal-title":"Cancer Res Treat."},{"key":"10.1016\/j.drup.2024.101195_bib286","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100916","article-title":"Overcoming cancer chemotherapy resistance by the induction of ferroptosis","volume":"66","author":"Wang","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"9","key":"10.1016\/j.drup.2024.101195_bib287","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/cr.2016.95","article-title":"Ferroptosis is an autophagic cell death process","volume":"26","author":"Gao","year":"2016","journal-title":"Cell Res"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib288","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1158\/2159-8290.CD-22-0411","article-title":"C\/EBPalpha confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia","volume":"13","author":"Sabatier","year":"2023","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib289","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40880-018-0288-x","article-title":"Amino acid transporter SLC7A11\/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer","volume":"38","author":"Koppula","year":"2018","journal-title":"Cancer Commun. (Lond. )"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib290","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/s41375-022-01573-6","article-title":"Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia","volume":"36","author":"Pardieu","year":"2022","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.drup.2024.101195_bib291","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2024.101195_bib292","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2016.00021","article-title":"Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy","volume":"6","author":"Bykov","year":"2016","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib293","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3324\/haematol.2020.259531","article-title":"APR-246 induces early cell death by ferroptosis in acute myeloid leukemia","volume":"107","author":"Birsen","year":"2022","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib294","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nchembio.72","article-title":"Mechanisms for copper acquisition, distribution and regulation","volume":"4","author":"Kim","year":"2008","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib295","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cbpa.2010.01.003","article-title":"Human copper homeostasis: a network of interconnected pathways","volume":"14","author":"Lutsenko","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib296","first-page":"4074","article-title":"Pan-cancer profiles of the cuproptosis gene set","volume":"12","author":"Liu","year":"2022","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.drup.2024.101195_bib297","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.biopha.2018.01.109","article-title":"Disulfiram\/copper causes ROS levels alteration, cell cycle inhibition, and apoptosis in acute myeloid leukaemia cell lines with modulation in the expression of related genes","volume":"99","author":"Hassani","year":"2018","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.drup.2024.101195_bib298","first-page":"17","article-title":"AC024896.1\/miR-363-3p axis regulates the malignant progression of acute myeloid leukemia by cuproptosis-related gene MYO1B","volume":"14","author":"Zhang","year":"2024","journal-title":"Blood Lymphat Cancer"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib299","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl4018","article-title":"SF3B1 mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia","volume":"10","author":"Moison","year":"2024","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib300","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/hmg\/ddl012","article-title":"The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron-sulfur cluster biogenesis","volume":"15","author":"Pondarre","year":"2006","journal-title":"Hum. Mol. Genet"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib301","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"6554","key":"10.1016\/j.drup.2024.101195_bib302","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/378303a0","article-title":"Syk tyrosine kinase required for mouse viability and B-cell development","volume":"378","author":"Cheng","year":"1995","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.drup.2024.101195_bib303","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: from bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.drup.2024.101195_bib304","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-19-0209","article-title":"Resistance mechanisms to SYK inhibition in acute myeloid leukemia","volume":"10","author":"Cremer","year":"2020","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib305","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/s41375-021-01222-4","article-title":"Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field","volume":"35","author":"Falini","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.drup.2024.101195_bib306","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib307","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2174\/1574892818666221207115016","article-title":"Gene expression network and Circ_0008012 promote progression in MLL\/AF4 positive acute lymphoblastic leukemia","volume":"18","author":"Tang","year":"2023","journal-title":"Recent Pat. Anticancer Drug Discov."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib308","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s43018-020-0052-4","article-title":"Spotlight on cancer genomics","volume":"1","author":"Anon","year":"2020","journal-title":"Nat. Cancer"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib309","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","article-title":"Menin: a scaffold protein that controls gene expression and cell signaling","volume":"38","author":"Matkar","year":"2013","journal-title":"Trends Biochem Sci."},{"issue":"5311","key":"10.1016\/j.drup.2024.101195_bib310","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"issue":"1-2","key":"10.1016\/j.drup.2024.101195_bib311","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0378-1119(00)00562-X","article-title":"Characterization of a MEN1 ortholog from Drosophila melanogaster","volume":"263","author":"Guru","year":"2001","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib312","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s003359901051","article-title":"Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene","volume":"10","author":"Guru","year":"1999","journal-title":"Mamm. Genome"},{"issue":"19","key":"10.1016\/j.drup.2024.101195_bib313","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1038\/sj.onc.1202164","article-title":"Characterization of the mouse Men1 gene and its expression during development","volume":"17","author":"Stewart","year":"1998","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib314","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1073\/pnas.0510347103","article-title":"The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5851","key":"10.1016\/j.drup.2024.101195_bib315","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.1146812","article-title":"Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus","volume":"318","author":"Karnik","year":"2007","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib316","first-page":"1556","article-title":"Menin expression is regulated by transforming growth factor beta signaling in leukemia cells","volume":"124","author":"Zhang","year":"2011","journal-title":"Chin. Med J. (Engl. )"},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib317","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1158\/0008-5472.CAN-05-4518","article-title":"Mutation of tumor suppressor gene Men1 acutely enhances proliferation of pancreatic islet cells","volume":"66","author":"Schnepp","year":"2006","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.drup.2024.101195_bib318","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1038\/sj.onc.1209400","article-title":"Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression","volume":"25","author":"La","year":"2006","journal-title":"Oncogene"},{"issue":"7386","key":"10.1016\/j.drup.2024.101195_bib319","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature10806","article-title":"The same pocket in menin binds both MLL and JUND but has opposite effects on transcription","volume":"482","author":"Huang","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib320","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib321","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.drup.2024.101195_bib322","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood.2020006575","article-title":"Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations","volume":"136","author":"Miao","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib323","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/PPO.0000000000000571","article-title":"Menin inhibitors in acute myeloid leukemia-what does the future hold?","volume":"28","author":"Swaminathan","year":"2022","journal-title":"Cancer J."},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib324","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib325","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.drup.2024.101195_bib326","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.drup.2024.101195_bib327","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1038\/s41375-020-0983-x","article-title":"Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy","volume":"34","author":"Venkataraman","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib328","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41375-020-0824-y","article-title":"A novel chimeric antigen receptor redirecting T-cell specificity towards CD26(+) cancer cells","volume":"35","author":"Zhou","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2024.101195_bib329","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1012981","article-title":"Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase","volume":"13","author":"Cui","year":"2022","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib330","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","article-title":"CML Hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor-engineered T Cells","volume":"79","author":"Warda","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib331","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2141.2011.08901.x","article-title":"CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia","volume":"156","author":"Ma","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"39","key":"10.1016\/j.drup.2024.101195_bib332","doi-asserted-by":"crossref","first-page":"16852","DOI":"10.1073\/pnas.1007896107","article-title":"CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia","volume":"107","author":"Uckun","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.drup.2024.101195_bib333","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2024.101195_bib334","doi-asserted-by":"crossref","first-page":"30","DOI":"10.20517\/cdr.2017.03","article-title":"Identification and targeting of CD22DeltaE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas","volume":"1","author":"Uckun","year":"2018","journal-title":"Cancer Drug Resist"},{"issue":"3","key":"10.1016\/j.drup.2024.101195_bib335","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijp.ijp_531_20","article-title":"Chimeric antigen receptor T cell: A cancer immunotherapy","volume":"54","author":"Singh","year":"2022","journal-title":"Indian J. Pharm."},{"issue":"25","key":"10.1016\/j.drup.2024.101195_bib336","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122379119","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.drup.2024.101195_bib337","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12943-023-01722-0","article-title":"Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment","volume":"22","author":"Gao","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2024.101195_bib338","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1285406","article-title":"Broadening the horizon: potential applications of CAR-T cells beyond current indications","volume":"14","author":"Karsten","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.drup.2024.101195_bib339","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1174138","article-title":"SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy","volume":"14","author":"Farhangnia","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.drup.2024.101195_bib340","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.reth.2019.11.003","article-title":"Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib","volume":"14","author":"Zhang","year":"2020","journal-title":"Regen. Ther."},{"key":"10.1016\/j.drup.2024.101195_bib341","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"4","key":"10.1016\/j.drup.2024.101195_bib342","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.drup.2024.101195_bib343","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.celrep.2017.07.075","article-title":"PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity","volume":"20","author":"Gato-Canas","year":"2017","journal-title":"Cell Rep."},{"issue":"7686","key":"10.1016\/j.drup.2024.101195_bib344","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.drup.2024.101195_bib345","doi-asserted-by":"crossref","first-page":"10841","DOI":"10.1007\/s00432-023-04974-x","article-title":"Association of CDKN2A\/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children","volume":"149","author":"Ruan","year":"2023","journal-title":"J. Cancer Res Clin. Oncol."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764624001535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764624001535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:52:16Z","timestamp":1774270336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764624001535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":345,"alternative-id":["S1368764624001535"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2024.101195","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress on gene mutations and drug resistance in leukemia","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2024.101195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101195"}}